Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.440
-0.050 (-1.43%)
At close: Nov 20, 2024, 4:00 PM
3.549
+0.109 (3.18%)
After-hours: Nov 20, 2024, 5:04 PM EST
Arbutus Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 6.74 | 18.14 | 39.02 | 10.99 | 6.91 | 6.01 | Upgrade
|
| Revenue Growth (YoY) | -69.69% | -53.51% | 255.11% | 58.92% | 15.02% | 1.11% | Upgrade
|
| Cost of Revenue | 62.79 | 73.7 | 84.41 | 65.5 | 49.34 | 57.6 | Upgrade
|
| Gross Profit | -56.05 | -55.56 | -45.39 | -54.51 | -42.42 | -51.59 | Upgrade
|
| Selling, General & Admin | 22.5 | 22.48 | 17.83 | 17.14 | 14.85 | 14.33 | Upgrade
|
| Operating Expenses | 22.5 | 22.48 | 17.83 | 17.14 | 14.85 | 16.36 | Upgrade
|
| Operating Income | -78.55 | -78.03 | -63.22 | -71.65 | -57.27 | -67.95 | Upgrade
|
| Interest Expense | -0.15 | -0.46 | -1.73 | -2.86 | -4.01 | -2.11 | Upgrade
|
| Interest & Investment Income | 6.59 | 5.69 | 2.19 | 0.13 | 0.74 | 2.11 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | -2.55 | -22.52 | Upgrade
|
| Currency Exchange Gain (Loss) | -0 | 0.03 | -0.02 | 0.01 | -0.12 | 0.04 | Upgrade
|
| EBT Excluding Unusual Items | -72.11 | -72.78 | -62.78 | -74.38 | -63.21 | -90.42 | Upgrade
|
| Merger & Restructuring Charges | -3.63 | - | - | - | -0.06 | -0.16 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | - | -22.47 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -43.84 | Upgrade
|
| Other Unusual Items | -0.96 | -0.07 | -2.23 | -1.87 | -0.47 | -9.49 | Upgrade
|
| Pretax Income | -76.7 | -72.85 | -65.01 | -76.25 | -63.75 | -166.38 | Upgrade
|
| Income Tax Expense | - | - | 4.44 | - | - | -12.66 | Upgrade
|
| Net Income | -76.7 | -72.85 | -69.46 | -76.25 | -63.75 | -153.72 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | 12.14 | 12.12 | 11.15 | Upgrade
|
| Net Income to Common | -76.7 | -72.85 | -69.46 | -88.39 | -75.87 | -164.87 | Upgrade
|
| Shares Outstanding (Basic) | 180 | 166 | 151 | 106 | 76 | 57 | Upgrade
|
| Shares Outstanding (Diluted) | 180 | 166 | 151 | 106 | 76 | 57 | Upgrade
|
| Shares Change (YoY) | 10.83% | 9.95% | 42.07% | 40.10% | 32.83% | 3.24% | Upgrade
|
| EPS (Basic) | -0.43 | -0.44 | -0.46 | -0.83 | -1.00 | -2.89 | Upgrade
|
| EPS (Diluted) | -0.43 | -0.44 | -0.46 | -0.83 | -1.00 | -2.89 | Upgrade
|
| Free Cash Flow | -71.92 | -86.94 | -35.87 | -68.34 | -51.67 | -71.6 | Upgrade
|
| Free Cash Flow Per Share | -0.40 | -0.52 | -0.24 | -0.64 | -0.68 | -1.25 | Upgrade
|
| Gross Margin | - | - | -116.33% | - | - | - | Upgrade
|
| Operating Margin | -1165.03% | -430.15% | -162.03% | -652.07% | -828.30% | -1130.34% | Upgrade
|
| Profit Margin | -1137.64% | -401.57% | -178.01% | -804.39% | -1097.31% | -2742.84% | Upgrade
|
| Free Cash Flow Margin | -1066.79% | -479.27% | -91.92% | -621.96% | -747.32% | -1191.07% | Upgrade
|
| EBITDA | -77.14 | -76.63 | -61.8 | -69.9 | -55.29 | -65.92 | Upgrade
|
| EBITDA Margin | - | - | -158.37% | - | - | - | Upgrade
|
| D&A For EBITDA | 1.41 | 1.4 | 1.43 | 1.75 | 1.98 | 2.03 | Upgrade
|
| EBIT | -78.55 | -78.03 | -63.22 | -71.65 | -57.27 | -67.95 | Upgrade
|
| EBIT Margin | - | - | -162.03% | - | - | - | Upgrade
|
| Revenue as Reported | 6.74 | 18.14 | 39.02 | 10.99 | 6.91 | 6.01 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.